# CellFE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellfe

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.cellfebiotech.com
- Total disclosed funding: $16M
- Latest round: Series A (Jul 14, 2023)
- Investors on record: 10

## About

CellFE Inc., based in California, specializes in advanced microfluidic technologies that enhance the development and delivery of cell therapies, helping researchers overcome challenges in scalability and efficiency.Founded in 2018 in San Carlos, California, CellFE Inc. focuses on biotechnological advancements in cell therapy. The company was established by a team including Alexander Alexeev, Alla Zamarayeva, and Todd Sulchek, with Alla Zamarayeva serving as the CEO. The company has previously engaged in 2 investment deals, with its most recent funding round occurring on July 14, 2023, when CellFE raised USD 11.04 mn in a SERIES A funding led by M Ventures and supported by other investors such as Cota Capital and Khosla Ventures. The total amount raised by CellFE to date stands at USD 11.04 mn, with a current company valuation of USD 70.239 mn.CellFE specializes in advanced microfluidic-based technologies that facilitate the development and delivery of cell therapies. Their flagship product, the CellFE system, is a benchtop device designed to streamline research and process development in cell therapy applications. The technology is engineered to enhance cell health, enable high yields, and support rapid and complex genome editing without the use of viral vectors. CellFE’s solutions primarily target cell therapy researchers and developers aiming to overcome challenges related to scalability, manufacturing costs, and vein-to-vein times, ultimately making lifesaving therapies more accessible to patients. The company serves a global market, focusing on regions with advanced biomedical research facilities and burgeoning cell therapy sectors, particularly in North America, Europe, and parts of Asia.CellFE’s revenue model is based on direct sales of its core products, such as the CellFE system and related technologies, to research institutions, biotech firms, and pharmaceutical companies engaged in cell therapy. Transactions typically involve B2B partnerships, where customers purchase equipment and technology licenses for specific applications in their research or manufacturing processes. Additionally, the company may offer subscription-based access to software or ongoing support services, tailoring their offerings to the unique needs of each client. The structure of these transactions emphasizes long-term relationships, where the value is derived from the effective implementation of CellFE’s technology in clinical and commercial settings. Specific pricing details for their products and services are set according to the complexity and scale of the projects undertaken by their clients.In July 2023, CellFE Inc. secured USD 11.04 mn in SERIES A funding, led by M Ventures, to enhance its technology platform. The company intends to utilize this funding for the development of new products and expansions into additional markets. Plans include targeting regions with emerging cell therapy initiatives and strengthening its presence in North America and Europe. Specific timelines for these expansions are ongoing as the company assesses market opportunities.

## Funding rounds

- Series A, Jul 14, 2023, $11M — Khosla Ventures, Elm Street Ventures, GreatPoint Ventures, Cota Capital, Embark Ventures, M Ventures, Dynamk Capital, EGB Capital, Riverine Ventures
- Seed, Mar 31, 2020, $4.8M — Elm Street Ventures, Cota Capital, Embark Ventures, Dynamk Capital, McEwan Lane Family Trust

## Investors

- Elm Street Ventures (https://capitalatlas.ai/funds/elm-street-ventures) — Seed, Series A
- Cota Capital (https://capitalatlas.ai/funds/cota-capital) — Seed, Series A
- Embark Ventures (https://capitalatlas.ai/funds/embark-ventures) — Seed, Series A
- Dynamk Capital (https://capitalatlas.ai/funds/dynamk-capital) — Seed, Series A
- McEwan Lane Family Trust — Seed
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A
- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- EGB Capital (https://capitalatlas.ai/funds/egb-capital) — Series A
- Riverine Ventures (https://capitalatlas.ai/funds/riverine-ventures) — Series A